SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...
Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...
At the 44 th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
2don MSNOpinion
Moderna chair says US assault on science is just beginning
Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that ...
Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large ...
Jan 12 (Reuters) - Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the ...
Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...
If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable ...
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44 th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 ...
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback